| Karen A Gillan, AU | |
|
2725 Capitol Ave, #404, Sacramento, CA 95816-6004 | |
| (916) 262-9456 | |
| (916) 262-9460 |
| Full Name | Karen A Gillan |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 28 Years |
| Location | 2725 Capitol Ave, Sacramento, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386755601 | NPI | - | NPPES |
| AU0017200 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | AU1720 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Valley Medical Foundation | 9830094515 | 1840 |
News Archive
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
News outlets report that the next step for some GOP lawmakers will revolve around a budget plan that will end deficits by 2023. Along those lines, House Budget Committee Chairman Paul Ryan, R-Wis., has suggested a change in his Medicare plan.
Johnson & Johnson provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE (infliximab) and SIMPONI (golimumab) in markets outside the United States. The amended agreement announced today in a separate news release from both companies concludes a pending arbitration, which had been filed by Johnson & Johnson in May 2009.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 4 days ago
| Provider Name | Sutter Valley Medical Foundation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669846986 PECOS PAC ID: 9830094515 Enrollment ID: O20090311000335 |
News Archive
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
News outlets report that the next step for some GOP lawmakers will revolve around a budget plan that will end deficits by 2023. Along those lines, House Budget Committee Chairman Paul Ryan, R-Wis., has suggested a change in his Medicare plan.
Johnson & Johnson provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE (infliximab) and SIMPONI (golimumab) in markets outside the United States. The amended agreement announced today in a separate news release from both companies concludes a pending arbitration, which had been filed by Johnson & Johnson in May 2009.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karen A Gillan, AU 10470 Old Placerville Rd Ste 100, Sacramento, CA 95827-2539 Ph: (800) 470-0071 | Karen A Gillan, AU 2725 Capitol Ave, #404, Sacramento, CA 95816-6004 Ph: (916) 262-9456 |
News Archive
Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.
News outlets report that the next step for some GOP lawmakers will revolve around a budget plan that will end deficits by 2023. Along those lines, House Budget Committee Chairman Paul Ryan, R-Wis., has suggested a change in his Medicare plan.
Johnson & Johnson provided additional information today on its amended agreement with Merck regarding distribution rights for REMICADE (infliximab) and SIMPONI (golimumab) in markets outside the United States. The amended agreement announced today in a separate news release from both companies concludes a pending arbitration, which had been filed by Johnson & Johnson in May 2009.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 4 days ago
Tyler Christian Oakes, AUD. Audiologist Medicare: Medicare Enrolled Practice Location: 7300 Wyndham Dr, Sacramento, CA 95823 Phone: 916-525-6280 Fax: 916-525-6285 | |
Mrs. Tara Rene Roberts, MS, CCC-A Audiologist Medicare: Medicare Enrolled Practice Location: 2025 Morse Ave, Head And Neck Surgery Department - 3e, Sacramento, CA 95825 Phone: 916-973-7913 Fax: 916-973-7971 | |
Alasia Fate, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1111 Exposition Blvd Bldg 700, Sacramento, CA 95815 Phone: 916-736-3399 Fax: 916-233-4179 | |
Mrs. Ann Marie Mullen, MS Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5342 Dudley Blvd., Sacramento, CA 95652 Phone: 916-561-7400 | |
Cynthia Powell Fetherston, M.S Audiologist Medicare: Not Enrolled in Medicare Practice Location: 2025 Morse Ave, Sacramento, CA 95825 Phone: 916-973-7991 Fax: 916-973-7971 | |
Dr. Phoebe Parnelle Sewell, AUD Audiologist Medicare: Medicare Enrolled Practice Location: 7300 Wyndham Dr, Sacramento, CA 95823 Phone: 916-525-6350 Fax: 916-525-6368 | |
Jannette Lee Ann Palermo, MS Audiologist Medicare: Medicare Enrolled Practice Location: 3180 Arden Way, Sacramento, CA 95825 Phone: 916-977-3277 Fax: 916-977-3275 |